$INTI
Inhibitor Therapeutics, Inc.

2014 Q2 Form 10-Q Financial Statement

#000119312514194777 Filed on May 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $190.0K $160.0K $90.00K
YoY Change -34.48% 77.78% -10.0%
% of Gross Profit
Research & Development $1.930M $25.33K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.116M $186.9K $90.55K
YoY Change 424.22% 106.45% -17.69%
Operating Profit -$2.116M -$186.9K -$90.55K
YoY Change 424.22% 106.45%
Interest Expense $24.99K $9.558K
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $30.00K
YoY Change -100.0% -100.0% 200.0%
Pretax Income -$2.140M -$200.0K -$60.00K
YoY Change 692.59% 233.33% -45.45%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.141M -$196.5K -$60.55K
YoY Change 702.03% 224.53% -44.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.10 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 18.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $270.0K $0.00 $780.0K
YoY Change -100.0% -37.6%
Cash & Equivalents $271.2K $456.00 $857.7K
Short-Term Investments
Other Short-Term Assets $29.29K $10.00K $110.0K
YoY Change -90.91% 120.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $300.5K $10.46K $880.0K
YoY Change -98.81% -32.31%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $300.5K $10.46K $880.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $300.5K $10.46K $880.0K
YoY Change -98.81% -32.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $280.2K $355.1K $370.0K
YoY Change 100.12% -4.03% 2.78%
Accrued Expenses $20.00K $0.00 $190.0K
YoY Change -66.67% -100.0% 5.56%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $80.00K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $453.9K $972.8K $570.0K
YoY Change 46.41% 70.66% 5.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $510.0K
YoY Change -8.93%
Total Long-Term Liabilities $0.00 $0.00 $510.0K
YoY Change -100.0% -58.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $453.9K $972.8K $570.0K
Total Long-Term Liabilities $0.00 $0.00 $510.0K
Total Liabilities $450.0K $970.0K $1.080M
YoY Change 45.16% -10.19% -39.33%
SHAREHOLDERS EQUITY
Retained Earnings -$30.58M -$28.44M
YoY Change
Common Stock $4.142K $1.889K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$153.4K -$962.3K -$190.0K
YoY Change
Total Liabilities & Shareholders Equity $300.5K $10.46K $880.0K
YoY Change -98.81% -32.31%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$2.141M -$196.5K -$60.55K
YoY Change 702.03% 224.53% -44.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$290.0K -$110.0K -$80.00K
YoY Change -65.88% 37.5% 14.29%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 560.0K 110.0K 0.000
YoY Change 700.0%
NET CHANGE
Cash From Operating Activities -290.0K -110.0K -80.00K
Cash From Investing Activities 0.000
Cash From Financing Activities 560.0K 110.0K 0.000
Net Change In Cash 270.0K 0.000 -80.00K
YoY Change -134.62% -100.0% 14.29%
FREE CASH FLOW
Cash From Operating Activities -$290.0K -$110.0K -$80.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
975000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18888971 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
776472
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.85
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
355097
CY2014Q1 us-gaap Notes Payable Current
NotesPayableCurrent
77701
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
972780
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-962324
CY2014Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
474874
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28444143
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
1889
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10456
CY2014Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62900
CY2014Q1 us-gaap Interest Payable Current
InterestPayableCurrent
2208
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Assets Current
AssetsCurrent
10456
CY2014Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
10000
CY2014Q1 us-gaap Assets
Assets
10456
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
456
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
0
CY2014Q1 hppi Working Capital Advances From Affiliates
WorkingCapitalAdvancesFromAffiliates
140000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
857702
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287072
CY2013Q4 us-gaap Notes Payable Current
NotesPayableCurrent
68428
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776053
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-765836
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
366130
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28247655
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1889
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10217
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1923
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10217
CY2013Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
10000
CY2013Q4 us-gaap Assets
Assets
10217
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2013Q1 hppi Percentage Of Issued And Outstanding Shares Of Common Stock
PercentageOfIssuedAndOutstandingSharesOfCommonStock
1.00 pure
CY2013Q1 hppi Ownership Exchanged For Assets Contributed
OwnershipExchangedForAssetsContributed
0.90 pure
CY2013Q2 hppi Number Of Former Executive Officers To Whom Restricted Shares Issued
NumberOfFormerExecutiveOfficersToWhomRestrictedSharesIssued
1 Office
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15560504 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-81230
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
CY2013Q1 us-gaap Revenues
Revenues
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28922
CY2013Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
30000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-90545
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-60545
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
90545
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
CY2013Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
8237
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-81230
CY2013Q1 us-gaap Interest Expense
InterestExpense
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
CY2013Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
90545
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18888971 shares
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-186930
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-196488
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
161605
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
108744
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-108505
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2014Q1 us-gaap Revenues
Revenues
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
CY2014Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
CY2014Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
81317
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
239
CY2014Q1 us-gaap Interest Expense
InterestExpense
9558
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25325
CY2014Q1 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
108744
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
6666
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
186930
CY2014Q1 hppi Sharebased Compensation Arrangement Purchase Price Of Common Stock Percent Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementPurchasePriceOfCommonStockPercentRelatedToSpecificVotingStockPercentage
1.10 pure
CY2014Q1 hppi Minimum Specified Voting Stock Percentage Under Incentive Stock Plan
MinimumSpecifiedVotingStockPercentageUnderIncentiveStockPlan
0.10 pure
CY2014Q1 hppi Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Related To Specific Voting Stock Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodRelatedToSpecificVotingStockPercentage
P5Y
CY2014Q1 hppi Supply And License Agreement Term Duration From First Commercial Transaction
SupplyAndLicenseAgreementTermDurationFromFirstCommercialTransaction
P10Y

Files In Submission

Name View Source Status
0001193125-14-194777-index-headers.html Edgar Link pending
0001193125-14-194777-index.html Edgar Link pending
0001193125-14-194777.txt Edgar Link pending
0001193125-14-194777-xbrl.zip Edgar Link pending
d706409d10q.htm Edgar Link pending
d706409dex311.htm Edgar Link pending
d706409dex312.htm Edgar Link pending
d706409dex321.htm Edgar Link pending
d706409dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20140331.xml Edgar Link completed
hppi-20140331.xsd Edgar Link pending
hppi-20140331_cal.xml Edgar Link unprocessable
hppi-20140331_def.xml Edgar Link unprocessable
hppi-20140331_lab.xml Edgar Link unprocessable
hppi-20140331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending